284 related articles for article (PubMed ID: 28103444)
1. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2017 Mar; 16(3):405-410. PubMed ID: 28103444
[TBL] [Abstract][Full Text] [Related]
2. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
3. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
[TBL] [Abstract][Full Text] [Related]
4. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
Raso S; Hermans C
Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
[TBL] [Abstract][Full Text] [Related]
5. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
Musso R
Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
8. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
10. Simoctocog alfa for the treatment of hemophilia A.
Morfini M
Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
[TBL] [Abstract][Full Text] [Related]
13. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
[TBL] [Abstract][Full Text] [Related]
14. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
16. Safety of recombinant coagulation factors in treating hemophilia.
Morfini M; Rapisarda CAP
Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
[TBL] [Abstract][Full Text] [Related]
17. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
19. Simoctocog alfa (Nuwiq
Klukowska A; Sidonio RF; Young G; Mancuso ME; Álvarez-Román MT; Bhatnagar N; Jansen M; Knaub S
Ther Adv Hematol; 2024; 15():20406207241245511. PubMed ID: 38737006
[TBL] [Abstract][Full Text] [Related]
20. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
